This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Edwards, L. A. Articles by Bally, M. B. Search for Related Content PubMed PubMed Citation Articles by Edwards, L. A. Articles by Bally, M. B.

Departments of ¹ Advanced Therapeutics, ² Medical Oncology, and ³ Cancer Genetics, BC Cancer Agency; Departments of ⁴ Pathology and Laboratory Medicine and ⁵ Biochemistry and Molecular Biology; and ⁶ Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, Canada

Requests for reprints: Marcel B. Bally, Department of Advanced Therapeutics, BC Cancer Agency, Vancouver, British Columbia, Canada. Phone: 604-675-8020; Fax: 604-675-8183. E-mail: mbally{at}bccrc.ca

The present study uses cell-based screening assays to assess the anticancer effects of targeting phosphatidylinositol 3-kinase–regulated integrin-linked kinase (ILK) in combination with small-molecule inhibitors of Raf-1 or mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase kinase (MEK). The objective was to determine if synergistic interactions are achievable through the use of agents targeting two key cell signaling pathways involved in regulating glioblastoma cancer. The phosphatidylinositol 3-kinase/protein kinase B (PKB)/Akt and the Ras/MAPK pathway were targeted for their involvement in cell survival and cell proliferation, respectively. The glioblastoma cell lines U87MG, SF-188, and U251MG were transiently transfected with an antisense oligonucleotide targeting ILK (ILKAS) alone or in combination with the Raf-1 inhibitor GW5074 or with the MEK inhibitor U0126. Dose and combination effects were analyzed by the Chou and Talalay median-effect method and indicated that combinations targeting ILK with either Raf-1 or MEK resulted in a synergistic interaction. Glioblastoma cells transfected with ILKAS exhibited reduced levels of ILK and phosphorylated PKB/Akt on Ser⁴⁷³ but not PKB/Akt on Thr³⁰⁸ as shown by immunoblot analysis. These results were confirmed using glioblastoma cells transfected with ILK small interfering RNA, which also suggested enhanced gene silencing when used in combination with U0126. U87MG glioblastoma cells showed a 90% (P < 0.05) reduction in colony formation in soft agar with exposure to ILKAS in combination with GW5074 compared with control colonies. A substantial increase in Annexin V–positive cells as determined by using fluorescence-activated cell sorting methods were seen in combinations that included ILKAS. Combinations targeting ILK and components of the Ras/MAPK pathway result in synergy and could potentially be more effective against glioblastoma cancer than monotherapy. [Mol Cancer Ther 2006;5(3):645–54]

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received 4/ 4/05; revised 12/30/05; accepted 1/12/06.

This article has been cited by other articles:

				P. C. McDonald, A. B. Fielding, and S. Dedhar Integrin-linked kinase - essential roles in physiology and cancer biology J. Cell Sci., October 1, 2008; 121(19): 3121 - 3132. [Abstract] [Full Text] [PDF]

				E. U. Alejandro and J. D. Johnson Inhibition of Raf-1 Alters Multiple Downstream Pathways to Induce Pancreatic -Cell Apoptosis J. Biol. Chem., January 25, 2008; 283(4): 2407 - 2417. [Abstract] [Full Text] [PDF]

				B. B. Friday and A. A. Adjei Advances in Targeting the Ras/Raf/MEK/Erk Mitogen-Activated Protein Kinase Cascade with MEK Inhibitors for Cancer Therapy Clin. Cancer Res., January 15, 2008; 14(2): 342 - 346. [Abstract] [Full Text] [PDF]

				E. L. Kwak, J. W. Clark, and B. Chabner Targeted Agents: The Rules of Combination Clin. Cancer Res., September 15, 2007; 13(18): 5232 - 5237. [Abstract] [Full Text] [PDF]

				A. B. Hjelmeland, K. P. Lattimore, B. E. Fee, Q. Shi, S. Wickman, S. T. Keir, M. D. Hjelmeland, D. Batt, D. D. Bigner, H. S. Friedman, et al. The combination of novel low molecular weight inhibitors of RAF (LBT613) and target of rapamycin (RAD001) decreases glioma proliferation and invasion Mol. Cancer Ther., September 1, 2007; 6(9): 2449 - 2457. [Abstract] [Full Text] [PDF]

				N. Skobeleva, S. Menon, L. Weber, E. A. Golemis, and V. Khazak In vitro and in vivo synergy of MCP compounds with mitogen-activated protein kinase pathway- and microtubule-targeting inhibitors Mol. Cancer Ther., March 1, 2007; 6(3): 898 - 906. [Abstract] [Full Text] [PDF]

				S. Naska, K. J. Park, G. E. Hannigan, S. Dedhar, F. D. Miller, and D. R. Kaplan An Essential Role for the Integrin-Linked Kinase-Glycogen Synthase Kinase-3{beta} Pathway during Dendrite Initiation and Growth J. Neurosci., December 20, 2006; 26(51): 13344 - 13356. [Abstract] [Full Text] [PDF]